An immunoglobulin-Y (IgY) ingredient marketed as Muno-IgY by IGY Life Sciences was found in a clinical study to support increased markers of immune function, exercise-related physical stress, upper respiratory symptom frequency, and gut microbiome profiles in healthy young adults.

Muno-IgY is a targeted immunoglobulin Y ingredient derived from hen egg yolk and developed to support gut and immune function through selective binding interactions within the gastrointestinal tract. IgY antibodies support immune and microbial balance by binding to specific pathogens and toxins while preserving beneficial microbiota.

After 12 weeks of supplementation, a population of 28 healthy adults experienced:  

• Trends toward reduced frequency of self-reported upper respiratory symptoms in the study population
• Significantly higher serum immunoglobulin A levels 24 hours after standardized exercise, indicating enhanced immune responsiveness to physiological stress
• Favorable reductions in lactate dehydrogenase (LDH), a biomarker associated with exercise-induced muscle stress
• Shifts in gut microbiome composition

The ingredient had a strong safety and tolerability profile throughout the 12-week supplementation period, authors said, with no serious adverse events reported.

“This publication represents an important step in advancing the scientific understanding of IgY supplementation in healthy adults,” said Dr. Paul E. Kilgore, co-author of the study. “While this was a pilot study and now powered for definitive efficacy conclusions, the consistent trends observed across immune, respiratory, and exercise-related endpoints support further research.”